MLICM
BCLI

Metropolitan Life Insurance Company (MetLife)’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-606
Closed -$154K – 2541
2020
Q3 		$154K Hold
606
– – ﹤0.01% 1943
2020
Q2 		$102K Buy
+606
New +$65.3K ﹤0.01% 2249

Other funds holding BCLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s BCLI Position: Q4 2020 in Review

Metropolitan Life Insurance Company (MetLife) sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2020, closing a stake of 606 shares — an estimated $154K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in BCLI in Q2 2020 and held it in 2 quarters. The position peaked at $154K in Q3 2020. 90 funds tracked by Wall St. Rank hold BCLI as of Q4 2020.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2020 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 606 BRAINSTORM CELL THERAPUTC shares in Q4 2020, an estimated $154K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 2 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s BRAINSTORM CELL THERAPUTC position peaked at $154K in Q3 2020.
  • 90 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2020.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2020, filed 16 Feb 2021.